Incannex Healthcare Inc

For the period ended Dec 31, 2023. Filed Feb 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2023 · Filed Feb 14, 2024

IXHL$2.01-8.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	For the three months ended December 31,		For the six months ended December 31,
	2023	2022	2023	2022
Operating expenses:
Research and development	2,638	1,549	5,247	2,959
Acquisition of in-process research and development	-	-	-	35,347
General and administrative	5,345	2,090	7,629	3,521
Total operating expenses	7,983	3,639	12,876	41,827
Loss from operations	(7,983)	(3,639)	(12,876)	(41,827)
Other income/(expense), net:	-	-	-	-
R&D tax incentive	2,727	666	6,824	680
Foreign exchange income/(expense)	(5)	-	(6)	-
Interest income	20	55	90	81
Total other income/(expense), net	2,742	721	6,908	761
Loss before income tax expense	(5,241)	(2,918)	(5,968)	(41,066)
Income tax expense	-	-	-	-
Net loss	$(5,241)	$(2,918)	$(5,968)	$(41,066)
Other comprehensive income/(loss):			-
Currency translation adjustment, net of tax	927	3,684	418	(1,827)
Total comprehensive income/(loss)	$(4,314)	$766	$(5,550)	$(42,893)
Net loss per share: Basic and diluted	$(0.33)	$0.05	$(0.38)	$(2.76)
Weighted average number of shares outstanding, basic and diluted	15,873,113	15,398,367	15,873,113	14,901,631

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.